Internal Medicine, Endocrinology, Diabetes, & Metabolism · Burlington, NC
NPI
1710047311
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1234 Huffman Mill Road
Burlington, NC, 27215
Phone (336) 538-1234
Groups this clinician bills Medicare through
Medicare paid, 2024
$177K
8,747 services
Medicare patients, 2024
517
Average age 74
Drug cost, 2024
$3.5M
8,135 prescriptions
Company payments, 2025
$151K
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas L O'Connell was code J0897 (injection, denosumab, 1 mg), 4,500 times for 44 patients. In total Thomas L O'Connell billed 8,747 services in 36 codes, and Medicare paid $177K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-03-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 4,500 | 44 | $18.45 | $83K |
| 99214 Office E&M - Established | Office | 588 | 328 | $81.41 | $48K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 454 | 302 | $11.01 | $4,998 |
| 36415 Venipuncture Blood Collection | Office | 331 | 227 | $8.62 | $2,855 |
| 83036 Blood Count | Office | 327 | 179 | $9.19 | $3,004 |
| 95251 Test - Miscellaneous | Office | 191 | 87 | $24.16 | $4,614 |
| 84443 Clinical Chemistry | Office | 190 | 150 | $16.12 | $3,064 |
| 77080 Standard X-ray | Office | 170 | 170 | $13.97 | $2,374 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 115 | 23 | $4.95 | $569 |
| 96372 Injection Administration | Office | 80 | 44 | $8.64 | $691 |
| 80053 Clinical Chemistry | Office | 61 | 56 | $9.86 | $602 |
| 80048 Clinical Chemistry | Office | 58 | 58 | $8.29 | $481 |
| 80061 Clinical Chemistry | Office | 54 | 51 | $12.68 | $685 |
| 76536 Ultrasound - Nonspecific | Office | 52 | 51 | $52.20 | $2,714 |
| 84439 Clinical Chemistry | Office | 51 | 33 | $8.15 | $415 |
By year: 2022 $130K for 5,261 services; 2023 $159K for 7,423 services; 2024 $177K for 8,747 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 331 | 227 | $8.62 | $2,855 |
| 83036 Blood Count | 327 | 179 | $9.19 | $3,004 |
| 84443 Clinical Chemistry | 190 | 150 | $16.12 | $3,064 |
| 80053 Clinical Chemistry | 61 | 56 | $9.86 | $602 |
| 80048 Clinical Chemistry | 58 | 58 | $8.29 | $481 |
| 80061 Clinical Chemistry | 54 | 51 | $12.68 | $685 |
| 82570 Clinical Chemistry | 51 | 48 | $4.98 | $254 |
| 84439 Clinical Chemistry | 51 | 33 | $8.15 | $415 |
| 82043 Clinical Chemistry | 50 | 47 | $5.55 | $277 |
| 82607 Clinical Chemistry | 44 | 40 | $13.44 | $591 |
Medicare prescription drug claims, 2024
In 2024, the drug Thomas L O'Connell prescribed most often to Medicare patients was Ozempic (Semaglutide), with 778 prescriptions and refills. In total Thomas L O'Connell wrote 8,135 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 778 | 897 | 125 | $832K |
| Jardiance Empagliflozin | 509 | 691 | 82 | $372K |
| Levothyroxine Sodium Generic | 504 | 1,394 | 148 | $5,562 |
| Metformin Hcl Generic | 429 | 1,099 | 113 | $3,259 |
| Mounjaro Tirzepatide | 391 | 455 | 59 | $480K |
| Metformin Hcl Er Metformin Hcl | 322 | 856 | 91 | $4,265 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 280 | 535 | 70 | $33K |
| Glimepiride Generic | 261 | 690 | 73 | $2,732 |
| Rosuvastatin Calcium Generic | 256 | 647 | 70 | $2,631 |
| Pioglitazone Hcl Generic | 251 | 630 | 69 | $3,083 |
| Methimazole Generic | 191 | 420 | 44 | $2,376 |
| Tresiba Flextouch U-200 Insulin Degludec | 179 | 296 | 41 | $208K |
| Glipizide Er Glipizide | 175 | 445 | 50 | $2,476 |
| Trulicity Dulaglutide | 172 | 227 | 41 | $221K |
| Humalog Kwikpen U-100 Insulin Lispro | 156 | 223 | 33 | $41K |
Brand drugs: 4,332 claims; generic drugs: 3,318 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas L O'Connell $151K ($151K in general payments such as food, travel and fees) from 13 companies. The largest payer was Insulet Corporation with $82K.
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation PODD | 151 | $82K |
| Sanofi-Aventis U.S. LLC SNY | 29 | $34K |
| Lilly USA, LLC LLY | 43 | $21K |
| Novo Nordisk Inc NVO | 20 | $14K |
| Madrigal Pharmaceuticals MDGL | 3 | $345 |
| Abbott Laboratories ABT | 11 | $268 |
| Sequel Med Tech, LLC | 2 | $216 |
| Dexcom, Inc. DXCM | 6 | $173 |
| Beta Bionics, Inc. BBNX | 1 | $172 |
| Ascendis Pharma Endocrinology Inc ASND | 5 | $171 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.